LADONNA SCHMIDT: Open Payments
NPI 1205857018 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,110 in 56 payments from 16 companies in 2025. Trend: 2023 $1,394 · 2024 $883 · 2025 $1,110
Food & beverage: $1,110
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $345 |
| Janssen Biotech, Inc. | 8 | $173 |
| Lilly USA, LLC | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| GENZYME CORPORATION | 3 | $80 |
| Gilead Sciences, Inc. | 3 | $61 |
| Intercept Pharmaceuticals, Inc. | 3 | $50 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
| QOL Medical, LLC | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
Products named: RINVOQ, TREMFYA, DUPIXENT, OMVOH, OCALIVA, XIFAXAN, MAVYRET, SKYRIZI.
Industry payments across IN — which companies pay providers there.
